shutterstock_761873647_-motortion-films
motortion films / Shutterstock.com
6 August 2020Big PharmaMuireann Bolger

Webinar: antibody patents in Europe and beyond

Antibody patenting can be a minefield for IP practitioners if they lack the most up-to-date knowledge about the best way to approach a patent application. Antibody experts and European patent attorneys Tom Leonard, Alison Care and Dave Wortley from law firm  Kilburn & Strode joined WIPR group editor Tom Phillips for a  webinar on the latest developments in antibody patenting yesterday, August 5.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.
Americas
27 February 2020   Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

More on this story

Americas
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.
Americas
27 February 2020   Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.

More on this story

Americas
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.
Americas
27 February 2020   Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.